Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.98M | $3.81M | $3.09M | $8.15M | — | — | — | — | — | $1.41M |
| Revenue growth | — | 27.9% | -19.0% | 163.8% | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | $57.2K |
| Gross margin | — | — | — | — | — | — | — | — | — | 4.0% |
| Operating income | -$51.3M | -$35.9M | -$29.6M | -$36.3M | -$36.8M | -$51.7M | -$63.1M | -$53.1M | -$71.7M | -$67.1M |
| Operating margin | -1723.3% | -941.4% | -960.1% | -445.6% | — | — | — | — | — | -4744.3% |
| Net income | -$53.3M | -$38.8M | -$30.1M | -$34.5M | -$35.2M | -$53.2M | -$66.1M | -$59.0M | -$75.4M | -$62.4M |
| Net margin | -1788.9% | -1019.3% | -974.6% | -423.8% | — | — | — | — | — | -4416.2% |
| EPS (diluted) | -$3.67 | -$1.80 | -$1.22 | -$1.98 | -$0.67 | -$0.35 | -$0.31 | -$4.72 | -$4.06 | -$1.79 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.5M | -$15.5M | -$33.0M | -$32.3M | -$31.8M | -$54.3M | -$56.7M | -$43.0M | -$68.8M | -$51.8M |
| Capital expenditures | $1.10M | $292K | $2.78M | $437K | — | — | — | — | — | — |
| Free cash flow | -$46.6M | -$15.8M | -$35.8M | -$32.7M | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.35M | $3.19M | $1.72M | $8.02M | $12.5M | $14.5M | $17.4M | $23.4M | $14.9M | $8.08M |
| Total assets | $25.4M | $20.7M | $22.3M | $17.1M | $19.7M | $22.8M | $28.5M | $32.3M | $28.8M | $18.6M |
| Total liabilities | $30.6M | $51.5M | $43.1M | $27.9M | $16.9M | $18.2M | $19.8M | $46.7M | $102M | $50.8M |
| Long-term debt | $2.23M | $151K | $98.5K | $50.3K | — | — | — | — | — | — |
| Shareholders' equity | -$5.17M | -$33.7M | -$25.5M | -$16.1M | $2.83M | $4.61M | $8.74M | -$14.4M | -$73.1M | -$32.2M |
| Retained earnings | -$147M | -$186M | -$216M | -$254M | -$290M | -$343M | -$409M | -$468M | -$543M | -$606M |
| Shares (wtd avg diluted) | 17.2M | 24.0M | 39.5M | 28.6M | 72.6M | 153M | 212M | 12.5M | 18.5M | 34.8M |
Every figure is extracted from Outlook Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.